HRP20110724T1 - Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba - Google Patents

Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba Download PDF

Info

Publication number
HRP20110724T1
HRP20110724T1 HR20110724T HRP20110724T HRP20110724T1 HR P20110724 T1 HRP20110724 T1 HR P20110724T1 HR 20110724 T HR20110724 T HR 20110724T HR P20110724 T HRP20110724 T HR P20110724T HR P20110724 T1 HRP20110724 T1 HR P20110724T1
Authority
HR
Croatia
Prior art keywords
mbp
basic protein
myelin basic
treatment
compositions
Prior art date
Application number
HR20110724T
Other languages
English (en)
Croatian (hr)
Inventor
Wraith David
Streeter Heather
Original Assignee
Apitope Technology (Bristol) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0721430A external-priority patent/GB0721430D0/en
Priority claimed from GB0800962A external-priority patent/GB0800962D0/en
Application filed by Apitope Technology (Bristol) Limited filed Critical Apitope Technology (Bristol) Limited
Publication of HRP20110724T1 publication Critical patent/HRP20110724T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Confectionery (AREA)
HR20110724T 2007-10-31 2008-10-30 Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba HRP20110724T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0721430A GB0721430D0 (en) 2007-10-31 2007-10-31 Composition
GB0800962A GB0800962D0 (en) 2008-01-18 2008-01-18 Conposition
PCT/GB2008/003673 WO2009056833A2 (en) 2007-10-31 2008-10-30 Composition

Publications (1)

Publication Number Publication Date
HRP20110724T1 true HRP20110724T1 (hr) 2011-12-31

Family

ID=40591554

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110724T HRP20110724T1 (hr) 2007-10-31 2008-10-30 Smjese koje sadrže peptide mijelinskog bazičnog proteina i njihova medicinska uporaba

Country Status (23)

Country Link
US (3) US8623827B2 (enExample)
EP (1) EP2211892B1 (enExample)
JP (1) JP5361895B2 (enExample)
KR (1) KR101570383B1 (enExample)
CN (1) CN101848725B (enExample)
AT (1) ATE518546T1 (enExample)
AU (1) AU2008320657B2 (enExample)
BR (1) BRPI0818302B1 (enExample)
CA (1) CA2703170C (enExample)
CY (1) CY1112620T1 (enExample)
DK (1) DK2211892T3 (enExample)
EA (1) EA017999B1 (enExample)
EC (1) ECSP10010211A (enExample)
HR (1) HRP20110724T1 (enExample)
IL (1) IL204662A (enExample)
MX (1) MX2010004698A (enExample)
MY (1) MY158800A (enExample)
NZ (1) NZ583924A (enExample)
PL (1) PL2211892T3 (enExample)
PT (1) PT2211892E (enExample)
SI (1) SI2211892T1 (enExample)
WO (1) WO2009056833A2 (enExample)
ZA (1) ZA201001748B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
KR101570383B1 (ko) 2007-10-31 2015-11-19 아피토프 테크놀러지 (브리스톨) 리미티드 조성물
JP5709876B2 (ja) 2009-10-12 2015-04-30 ライフバイオ ラボラトリーズ エルエルシーＬＩＦＥＢｉｏ ＬＡＢＯＲＡＴＯＲＩＥＳ ＬＬＣ 多発性硬化症治療用組成物
GB201300684D0 (en) * 2013-01-15 2013-02-27 Apitope Int Nv Peptide
GB201603582D0 (en) * 2016-03-01 2016-04-13 Apitope Int Nv Peptides
WO2018127828A1 (en) * 2017-01-04 2018-07-12 Apitope International Nv Therapeutic method using tolerogenic peptides
GB201700095D0 (en) * 2017-01-04 2017-02-22 Apitope Int Nv Composition
JP7419229B2 (ja) * 2017-08-14 2024-01-22 百明信康生物技術（浙江）有限公司 方法
IL307722A (en) 2021-04-16 2023-12-01 Cour Pharmaceuticals Dev Company Inc A method of monitoring the existence of immunological tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817629A (en) 1991-10-22 1998-10-06 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
KR20030062321A (ko) * 2000-08-21 2003-07-23 아피토프 테크놀러지 (브리스톨) 리미티드 펩티드 선별 방법
US20040096456A1 (en) 2000-12-01 2004-05-20 Conti-Fine Bianca M Method to treat hemophilia
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
KR101570383B1 (ko) 2007-10-31 2015-11-19 아피토프 테크놀러지 (브리스톨) 리미티드 조성물

Also Published As

Publication number Publication date
CA2703170C (en) 2016-10-11
BRPI0818302A2 (enExample) 2018-08-21
SI2211892T1 (sl) 2011-12-30
CN101848725B (zh) 2013-05-22
ZA201001748B (en) 2011-06-29
CN101848725A (zh) 2010-09-29
IL204662A (en) 2013-07-31
NZ583924A (en) 2012-06-29
MX2010004698A (es) 2010-05-13
JP5361895B2 (ja) 2013-12-04
MY158800A (en) 2016-11-15
WO2009056833A2 (en) 2009-05-07
BRPI0818302B1 (pt) 2022-04-12
DK2211892T3 (da) 2011-10-31
JP2011500776A (ja) 2011-01-06
EP2211892A2 (en) 2010-08-04
CA2703170A1 (en) 2009-05-07
WO2009056833A3 (en) 2009-11-26
KR101570383B1 (ko) 2015-11-19
HK1142803A1 (en) 2010-12-17
PL2211892T3 (pl) 2012-01-31
US20100286054A1 (en) 2010-11-11
EA017999B1 (ru) 2013-04-30
ECSP10010211A (es) 2010-08-31
US20160263188A1 (en) 2016-09-15
PT2211892E (pt) 2011-10-18
ATE518546T1 (de) 2011-08-15
US8623827B2 (en) 2014-01-07
US20140161832A1 (en) 2014-06-12
IL204662A0 (en) 2010-11-30
US9381234B2 (en) 2016-07-05
AU2008320657A1 (en) 2009-05-07
KR20100036391A (ko) 2010-04-07
EP2211892B1 (en) 2011-08-03
US9775880B2 (en) 2017-10-03
CY1112620T1 (el) 2016-02-10
EA201070541A1 (ru) 2010-12-30
AU2008320657B2 (en) 2013-09-05

Similar Documents

Publication Publication Date Title
AU2018201997B2 (en) Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions
WO2021207409A3 (en) Small molecule inhibitors of sars-cov-2 viral replication and uses thereof
BRPI0607326A2 (pt) composição de vacina, variante de peptìdeo de survivina, uso da referida composição, kit em partes e medicamento
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
BRPI0507966A (pt) uso de meloxicam para o tratamento de doenças respiratórias em porcos
FR15C0009I2 (fr) Compositions de gel phospholipide destinees a l'administration medicamenteuse et des methodes de traitement utilisant celles-ci
BRPI0408490A (pt) composições que compreendem ácidos graxos e aminoácidos
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
SG166125A1 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimeræs disease
BR102013003570A8 (pt) Composições de plasma rico em plaquetas
EA201071039A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение для лечения заболеваний, основанных на экспрессии mcp-1, cx3cr1 и p40
BR112013031652A2 (pt) métodos de tratamento para doenças retinais
ATE543804T1 (de) Neue verbindungen
CO2021000450A2 (es) Forma de dosificación farmacéutica administrable por vía oral con liberación modificada
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
DE602007002553D1 (de) Ihre verwendung zur herstellung einer therapeutisch und/oder prophylaktisch wirksamen pharmazeutischen zusammensetzung
RU2012157328A (ru) Лекарственное средство для профилактического и/или терапевтического лечения деменции по типу альцгеймера
JP2011500776A5 (enExample)
BRPI0720230B8 (pt) formulação nutricional oralmente administrável, uso da formulação, e, composição
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
EA202190334A1 (ru) Фармацевтическая лекарственная форма для перорального введения с модифицированным высвобождением
ATE518546T1 (de) Zusammensetzungen enthaltend myelin-basisches protein peptiden und medizinische verwendungen
CR9911A (es) Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain